Immunotech Biopharm Ltd
6978.HK
Get informed when a big investor buys or sells
+ FollowMarket Cap$250.09M
Close$
Share Statistics
| Market cap | $250.09 Million |
|---|---|
| Enterprise Value | $587.26 Million |
| Dividend Yield | $- (-) |
| Earnings per Share | $-0.42 |
| Beta | 0.12 |
| Outstanding Shares | 617,501,000 |
Return
| Return on Equity | 468.36% |
|---|---|
| Return on Assets | -81.79% |
| Return on Invested Capital | -1045.87% |
Valuation & Multiples
| P/E Ratio | -1.23 |
|---|---|
| PEG | 2.64 |
| Price to Sales | - |
| Price to Book Ratio | -0.4 |
| Enterprise Value to Revenue | - |
| Enterprise Value to EBIT | -1.79 |
| Enterprise Value to Net Income | -2 |
| Total Debt to Enterprise | 0.69 |
| Debt to Equity | -4.81 |
Revenue Sources
No data
Insider Trades
Last Earnings Call
Report Date
August 21, 2026
EPS Estimate
-
Average shareholder expectationRevenue Estimate
-
Average shareholder expectationNext Earnings Call
Expected Date
March 19, 2027
EPS Estimate
-
Average shareholder expectationRevenue Estimate
-
Average shareholder expectationInstitutional Sentiment (Put/Call)
No data available for the latest quarter.
Institutional Ownership
No data available for the latest quarter.
ESG Score
No data
About Immunotech Biopharm Ltd
189 employees
CEO: Jian Zhang Immunotech Biopharm Ltd operates as a biopharmaceutical firm specializing in cellular immunotherapy. Its primary activities involve the investigation, development, and market introduction of T cell-based immunotherapy solutions for vario...